Corbus Pharmaceuticals (CRBP) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising ...

Investment analysts at Lifesci Capital boosted their Q1 2025 earnings per share estimates for shares of Corbus ...

This was the stock's second consecutive day of losses.

Corbus Pharmaceuticals (CRBP) has been on a downward spiral lately with significant selling pressure. After declining 22.9% over the past four weeks, the stock looks well positioned for a trend ...

CRBP opened at $6.96 on Monday. Corbus Pharmaceuticals has a one year low of $6.38 and a one year high of $61.90. The stock’s fifty day moving average is $9.32 and its 200-day moving average is ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.